MAY 23, 2020 10:21 AM PDT

Can metformin treat lymphoma?

A popular diabetes medication may be useful in treating cancer, according to new research published recently in Cell Reports Medicine. The medication, biguanides, is most commonly known as metformin and is used to control blood sugar for people with Type 2 diabetes. The medication’s ability to target cell metabolism has interested cancer researchers for some time; this research adds to that interest by identifying a biomarker that could detect which cancers would respond to biguanides.

"Cancers vary widely in how they react to different therapies -- what works for one cancer type may not work for another -- but regardless, they are all reliant on metabolism for energy production," said senior author of the study and Van Andel Institute Professor Russell Jones, Ph.D. Dr. Jones is also the leader of VAI's Metabolic and Nutritional Programming group. 

Past attempts to use biguanides to treat cancer have been limited because of two main reasons: 1) it is difficult to predict which cancers will respond to treatment and 2) it is challenging to deliver enough of the drug into cancer cells so that it is effective. This study addresses the first concern.

"Our results establish two important things: First, they give us a way to objectively determine which types of cancer are sensitive to biguanide treatment and, second, they illuminate how and why some patients may respond better to biguanides than other patients," explains Dr. Jones. 

In the study, the research team found a microRNA regulated by the gene MYC that is a biomarker for cancers that respond to biguanide. MYC is a gene that is related to metabolic activity in cancer cells and that is present in many lymphomas. Watch the video below to learn more about the MYC gene.

This finding has significant implications, say the researchers. "Biguanides have great potential as cancer treatments, particularly for blood cancers," comments Dr. Jones. "Biomarkers such as what we have found here are vital tools for determining which cancers will respond to biguanides and which will not, which is important for patient care as well as designing more effective clinical trials."

Sources: Cell Reports Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAY 26, 2020
Genetics & Genomics
Some People May be Predisposed to Metastasis if They Get Cancer
MAY 26, 2020
Some People May be Predisposed to Metastasis if They Get Cancer
Cancer can occur for many reasons and is influenced by many different factors, including genes and the environment. But ...
JUN 13, 2020
Cannabis Sciences
CBD Kills Brain Cancer Cells in Petri Dish
JUN 13, 2020
CBD Kills Brain Cancer Cells in Petri Dish
Cannabis products are not only popular for their psychoactive effects. An increasing number of companies and researchers ...
JUN 26, 2020
Cancer
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
JUN 26, 2020
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immatu ...
JUL 08, 2020
Drug Discovery & Development
Common Blood Pressure Drugs May Prevent Colon Cancer
JUL 08, 2020
Common Blood Pressure Drugs May Prevent Colon Cancer
Colon cancer is the third most common cancer and the second leading cause of death by cancer around the world. Now, rese ...
JUL 13, 2020
Cancer
Workers in Transportation Might be More at Risk for Cancer
JUL 13, 2020
Workers in Transportation Might be More at Risk for Cancer
Road transportation workers are essential employees in any country. They represent truck, bus, taxi, and other such driv ...
JUL 24, 2020
Cancer
A New Biomarker Candidate for Cancer Diagnostics
JUL 24, 2020
A New Biomarker Candidate for Cancer Diagnostics
One of the best tools in the fight against cancer is diagnostics. In 2018, colorectal cancer was the second most lethal ...
Loading Comments...